Allogene Therapeutics Inc (NASDAQ:ALLO) had its Hold rating reiterated by JPMorgan Chase & Co. with a $29.00 price target

Allogene Therapeutics Inc (NASDAQ:ALLO) had its Hold rating reiterated by JPMorgan Chase & Co. with a $29.00 price target

Mar 11, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For Allogene Therapeutics Inc (NASDAQ:ALLO)

Today, JPMorgan Chase & Co. reiterated its Hold rating on Allogene Therapeutics Inc (NASDAQ:ALLO) with a price target of $29.00.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Allogene Therapeutics Inc (NASDAQ:ALLO) is Buy with a consensus target price of $33.6667 per share, a potential 18.63% upside.

Some recent analyst ratings include

  • 3/11/2019-Allogene Therapeutics Inc (NASDAQ:ALLO) had its Hold rating reiterated by JPMorgan Chase & Co. with a $29.00 price target
  • 3/8/2019-Allogene Therapeutics Inc (NASDAQ:ALLO) had its Buy rating reiterated by Cowen
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy ➝ Buy rating and $31.00 price target
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy ➝ Buy rating and $41.00 price target

Recent Trading Activity for Allogene Therapeutics Inc (NASDAQ:ALLO)
Shares of Allogene Therapeutics Inc closed the previous trading session at 28.38 â?’1.27 4.28% with 29.54 shares trading hands.

The post Allogene Therapeutics Inc (NASDAQ:ALLO) had its Hold rating reiterated by JPMorgan Chase & Co. with a $29.00 price target appeared first on Market Exclusive.

Read More Here...

Bookmark the permalink.